Polypharmacy and comorbidities among ambulatory cancer patients: A cross-sectional retrospective study.
Monira AlwhaibiYazed AlRuthiaTariq M AlhawassiHaya AlmalagHaya AlsalloumBander BalkhiPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)
Polypharmacy is highly prevalent in the Saudi Arabian oncology patients, especially in those with comorbidities like hypertension, diabetes, anxiety and asthma. Because polypharmacy mostly goes hand in hand with comorbidities, therefore, a multidisciplinary team approach of oncology pharmacist working with other healthcare providers to manage polypharmacy and simplify drug regimens for cancer patients is warranted to optimize the healthcare quality and improve drug safety.
Keyphrases
- healthcare
- adverse drug
- palliative care
- blood pressure
- end stage renal disease
- ejection fraction
- quality improvement
- type diabetes
- chronic kidney disease
- cardiovascular disease
- peritoneal dialysis
- prognostic factors
- emergency department
- adipose tissue
- glycemic control
- physical activity
- patient reported
- health information
- depressive symptoms
- social media
- saudi arabia